TMCnet News
Interleukin Genetics to Present at 2015 Marcum MicroCap ConferenceInterleukin Genetics, Inc. (OTCQB:ILIU) today announced that Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics, will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015, at 2:30 p.m. (ET) at the Grand Hyatt New York in New York City. The presentation will be webcast live and may be accessed at http://wsw.com/webcast/marcum3/iliu/index.aspx or by visiting the Company's website at www.ilgenetics.com. he webcast will also be available on the Company's website for a limited period of time following the conference. About Interleukin Genetics Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and to manage existing health and wellness through genetics-based insights and actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility and its Inherent Health® Weight Management Genetic Test that identifies the most effective diet and exercise programs for an individual, based on an individual's genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150519005206/en/ |
